Clinical Trials Browser

mirdametinib × Other hematologic neoplasm × 90 days × Clear all

NCT07061951 2026-06-01

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell